News2 mins ago
Capsida Biotherapeutics to Present New Preclinical Data on Potential of Systemically Delivered Next-Generation AAV Therapeutics for Treatment of Genetic Epilepsy
Preclinical data show IV administration of a next-generation gene therapy produced dose-dependent replacement of syntaxin-binding protein 1 (STXBP1) throughout the brain, with efficacy predictive of clinical...
